Evidence to Support a Change in Follow-up Policy for Patients with Breast Cancer: Time to First Relapse and Hazard Rate Analysis

Wheeler, T.K.; Stenning, Sally; Negus, S; Picken, S.; Metcalfe, Su

doi:10.1053/clon.1999.9035

Cited by 30 publications

(24 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With the consistently increasing number of new breast cancer cases each year and more women entering survivorship, it is worthwhile to reconsider the follow-up or surveillance schedules for women after primary treatment (31)(32)(33). For example, we shall plan to use the current available data and develop a practical statistical model to offer a schedule that considers known adverse prognostic factors.…”

Section: Discussionmentioning

confidence: 99%

Hazard of Recurrence among Women after Primary Breast Cancer Treatment—A 10-Year Follow-up Using Data from SEER-Medicare

Liu

Swartz

Zhao

et al. 2012

Cancer Epidemiology, Biomarkers &Amp; Prevention

109

View full text Add to dashboard Cite

Background: Few studies have used SEER-Medicare data to describe recurrence of breast cancer after primary treatment for U.S. women.Methods: We used SEER-Medicare data to estimate the annual hazard rate (HR) of recurrence for women with breast cancer between 1991 and 1997 with 10 years of follow-up. The Kaplan-Meier method was used to derive the HR. Multivariate Cox proportional hazards model was used to estimate the relative hazard of the recurrence-associated prognostic factors.Results: Of 20,027 women, 36.8% had recurrence within 10 years, with most of these recurrences (81.9%) occurring within 5 years after diagnosis. Women with stage III cancer showed the highest HR peak and largest magnitude than women with stage I or II disease (both P < 0.01) within the first 5 years. Women with negative tumor hormone receptor status had a higher peak hazard of developing recurrence within the first 5 years (P < 0.01), but the hazards were remarkably lower beyond 5 years of follow-up than in women with positive or unknown hormone receptor status (P > 0.05). Women with poorly differentiated histologic grade tumors showed higher HR in the first 5 years than women with other grades after primary treatment (both P < 0.01). The increased risk of recurrence of breast cancer was associated with advanced stage, moderate and poorly differently grades, and negative hormone receptor status (all P < 0.01).Conclusion: The HRs of the recurrence are dynamic over 10 years and are markedly determined by prognostic factors at diagnosis. Impact: Our study suggests that the optimal follow-up may differ among women. Cancer Epidemiol Biomarkers Prev; 21(5); 800-9. Ó2012 AACR.

show abstract

Section: Discussionmentioning

confidence: 99%

Hazard of Recurrence among Women after Primary Breast Cancer Treatment—A 10-Year Follow-up Using Data from SEER-Medicare

Liu

Swartz

Zhao

et al. 2012

Cancer Epidemiology, Biomarkers &Amp; Prevention

109

View full text Add to dashboard Cite

show abstract

“…However, there is much debate whether these objectives are met in current clinical practice [3,4]. First of all, routine follow-up with clinical examination has been shown not to contribute to improved survival [5-9]. Additionally, outpatient clinic visits have been identified as a transition time of high stress, generating increased anxiety because of the risk of detecting a recurrence [10].…”

Section: Introductionmentioning

confidence: 99%

Patient satisfaction with nurse-led telephone follow-up after curative treatment for breast cancer

et al. 2010

View full text Add to dashboard Cite

BackgroundCurrent frequent follow-up after treatment for breast cancer does not meet its intended aims, but does depend on expensive and scarce specialized knowledge for routine history taking and physical examinations. The study described in this paper compared patient satisfaction with a reduced follow-up strategy, i.e. nurse-led telephone follow-up, to satisfaction with traditional hospital follow-up.MethodsPatient satisfaction was assessed among patients (n = 299) who were participants of a randomized controlled trial investigating the cost-effectiveness of several follow-up strategies in the first year after treatment for breast cancer. Data on patient satisfaction were collected at baseline, three, six and 12 months after treatment, using the Dutch version of Ware's Patient Satisfaction Questionnaire III (PSQ III). In addition to general satisfaction, the PSQ III reports on satisfaction scores for technical competence, interpersonal aspects, and access of care. Regression analysis was used to predict satisfaction scores from whether or not nurse-led telephone follow-up was received.ResultsNurse-led telephone follow-up had no statistically significant influence on general patient satisfaction (p = 0.379), satisfaction with technical competence (p = 0.249), and satisfaction with interpersonal aspects (p = 0.662). Regarding access of care, patient satisfaction scores were significantly higher for patients receiving telephone follow-up (p = 0.015). However, a mean difference at 12 months of 3.1 points was judged to be not clinically relevant.ConclusionsNo meaningful differences were found in satisfaction scores between nurse-led telephone and hospital follow-up in the first year after breast cancer treatment. With high satisfaction scores and the potential to substantially reduce clinic visits, nurse-led telephone follow-up may be an acceptable alternative to traditional hospital follow-up.Trial registration numberISRCTN 74071417.

show abstract

“…The rising incidence of breast cancer and the advances in its treatment have led to a significant increase in the number of survivors after treatment for breast cancer. With finite resources, clinics could be targeting patients with a higher risk of relapse25, and breast cancer follow‐up could be individualized26.…”

Section: Discussionmentioning

confidence: 99%

Follow-up may not be beneficial after treatment of grade 1 breast cancer

Kontos

Allen

Trafalis

et al. 2009

British Journal of Surgery

View full text Add to dashboard Cite

show abstract

Evidence to Support a Change in Follow-up Policy for Patients with Breast Cancer: Time to First Relapse and Hazard Rate Analysis

Cited by 30 publications

References 8 publications

Hazard of Recurrence among Women after Primary Breast Cancer Treatment—A 10-Year Follow-up Using Data from SEER-Medicare

Hazard of Recurrence among Women after Primary Breast Cancer Treatment—A 10-Year Follow-up Using Data from SEER-Medicare

Patient satisfaction with nurse-led telephone follow-up after curative treatment for breast cancer

Follow-up may not be beneficial after treatment of grade 1 breast cancer

Contact Info

Product

Resources

About